Navigation Links
Shield Therapeutics Selects OpenClinica Enterprise
Date:1/5/2013

Waltham, MA & Wollerau, Switzerland (PRWEB) January 04, 2013

OpenClinica, LLC and Shield Therapeutics announces that Shield Therapeutics has selected the OpenClinica Enterprise software for its clinical data management needs related to the company’s clinical trials. Shield Therapeutics develops treatments for unmet medical needs, and is currently running a Phase III program for ST10, a novel orally delivered ferric iron-based therapy to treat iron deficiency.

“The OpenClinica system should enable us to collect data from participating clinical trial sites faster and with a higher level of quality,” said Carl Sterritt, Shield’s CEO. “We also hope that an added benefit of the OpenClinica Enterprise Edition will be facilitation of our regulatory compliance efforts.”

OpenClinica offers a unique and flexible model for its clinical trial software. “As commercial open source software, OpenClinica allows organizations like Shield Therapeutics to benefit from powerful, widely adopted, open source technology, while obtaining a fully supported implementation and a robust regulatory infrastructure, said Cal Collins, CEO at OpenClinica, LLC. “We are excited to welcome Shield Therapeutics to our rapidly growing community and Enterprise customer base.”

About Shield Therapeutics®

Shield Therapeutics is a Swiss-based specialty pharmaceutical company focused on the development and commercialization of novel mineral-based therapies to treat diseases with significant unmet medical need. The company was founded in 2008 and is currently undertaking a multi-national pivotal Phase III program for its lead asset, ST10, for the treatment of iron deficiency anaemia (IDA) associated with inflammatory bowel disease (IBD). For more information see http://www.shieldtx.com.

About OpenClinica®

OpenClinica enhances the productivity of clinical trials through commercial open source software. With over 1,000 implementations at biopharmaceutical companies, contract research organizations, academic, and government organizations worldwide, the OpenClinica software facilitates electronic data capture and data management, increasing the speed of collection and quality of data in clinical trials. OpenClinica supports HIPAA, 21 CFR Part 11, and other regulatory guidelines and is designed as a standards-based, extensible, and modular platform. For more information – including product downloads – visit http://www.openclinica.com or follow @OpenClinica on Twitter.

Read the full story at http://www.prweb.com/releases/sheild/clinical-trials/prweb10290102.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Molderizer and Safe Shield Get a Price Decrease; My Cleaning Products Says Its the Company's Christmas Treat
2. Mold Linked With Fatal Asthma and Allergy Attacks; Dr Mold Network Suggests Use of Molderizer and Safe Shield for Safer Mold Treatment
3. Christmas Special: My Cleaning Products Celebrates Holiday With a Molderizer and Safe Shield Markdown for its Clients
4. Pinnaclife Animal Health Features Seal N Heal Wound Shield in New Veterinary Dermatologist Tested and Approved Product Line!
5. Not your average heat shield
6. Agendia Signs Contract with Blue Shield of California
7. Cell Therapeutics, Inc.s (CTI) Board of Directors Approves Amendment of Shareholder Rights Plan
8. Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkins Lymphoma at
9. NKT Therapeutics Presents Data on Potential Antibody Treatment for Sickle Cell Disease
10. Cell Therapeutics Reports on Cooperative Group Sponsored Trial of Brostallicin in Patients with Metastatic Triple-Negative Breast Cancer
11. Smith & Nephew Announces Agreement To Acquire Assets Of Healthpoint Biotherapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... (PRWEB) , ... December 01, 2016 , ... ... congratulate long-term client Nanowear on their recent FDA Class II 510(k) clearance for ... a significant hurdle in commercializing remote cardiac monitoring devices that rely on cloth-based ...
(Date:12/2/2016)...   SurePure, Inc. (OTCQB: SURP) a global ... has concluded an agreement with Tamarack Biotics under which ... to acquire units of the Company,s patented photopurification technology ... Concurrently with the option, SurePure has ... will seek regulatory approvals in the United ...
(Date:11/30/2016)... ... November 30, 2016 , ... BEI ... Coil Actuator with a flexure design that ensures high alignment accuracy by preventing ... and is ideally suited where extreme precision is required, such as in medical ...
(Date:11/30/2016)... 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the ... excited to announce the formation of EyGen, Ltd. ... ophthalmology assets through proof of concept. EyGen,s lead ... Portage Pharmaceuticals Limited and being developed for topical ... anterior segment diseases. This agent has the potential ...
Breaking Biology Technology:
(Date:6/15/2016)... York , June 15, 2016 ... new market report titled "Gesture Recognition Market by Application ... Forecast, 2016 - 2024". According to the report, the  ... 11.60 billion in 2015 and is estimated to ... USD 48.56 billion by 2024.  Increasing ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
Breaking Biology News(10 mins):